Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Overview
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
AlzeCure Pharma AB
AnHeart Therapeutics Inc
Bayer AG
Boehringer Ingelheim Intertiol GmbH
Celon Pharma SA
Chronos Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Handok Inc
MimeTech Srl
Neurodegeneration Therapeutics Inc
Otonomy Inc
PharmatrophiX Inc
Takeda Pharmaceutical Co Ltd
Zebra Biologics Inc
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Drug Profiles
ACD-855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACD-856 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACD-857 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Agonize TrKB for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNN-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CH-7057288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTO-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize NTRK2 for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TRKB for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide Agonize TrkA and TrkB Alzheimer’s Disease and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TrkB for CNS Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEB-85 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Dormant Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Discontinued Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kise Receptor Type 2 or TrkB Tyrosine Kise or Tropomyosin Related Kise B or NTRK2 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Addex Therapeutics Ltd, H2 2019
Pipeline by AlzeCure Pharma AB, H2 2019
Pipeline by AnHeart Therapeutics Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Celon Pharma SA, H2 2019
Pipeline by Chronos Therapeutics Ltd, H2 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Pipeline by Exelixis Inc, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Handok Inc, H2 2019
Pipeline by MimeTech Srl, H2 2019
Pipeline by Neurodegeneration Therapeutics Inc, H2 2019
Pipeline by Otonomy Inc, H2 2019
Pipeline by PharmatrophiX Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Zebra Biologics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019